

Scientific Program

Day 1

July 27, 2015

08:00-09:00 Registrations



09:00-09:25

Opening Ceremony

Key Note	
09:25-09:30	Introduction
09:30-10:00	Allan Cripps Pro Vice chancellor, Griffith University, Australia
10:00-10:30	Nikolai Petrovsky President, Global Vaccines conferences, OMICS International, Research Director, Vaxine, Australia
Coffee Break: 10:30-10:45	

Track 1: Technologies for The Design, Discovery, Formulation and Administration of Vaccines

Track 2: Vaccines For Pregnant Women

Track 5: Recent Advances in Animal Vaccination

Track 6: Adjuvants for Human / Animal Vaccines

Track 9: Advancements in Vaccine Development

Session Chair: Nikolai Petrovsky, President, Global Vaccines conferences, OMICS International, Research Director, Vaxine, Australia

Session Introduction	
10:45-11:10	Rational vaccine design against complex pathogens in the OMICS era Denise Doolan, QIMR Berghofer, Australia
11:10-11:35	Development of a Passive RSV Vaccine for Infants as an Alternative to Maternal Vaccination Filip Dubovsky, MedImmune/AstraZeneca, USA
11:35-12:00	A dendritic cell-targetted vaccine loaded with a glyceraldehyde-3-phosphate dehydrogenase pe wide protection to listeriosis in susceptible and resistant mice Carmen Alvarez-Dominguez, Proteomics and Vaccines, Spain
12:00-12:25	Development and assessment of multivalent recombinant vaccines for bovine respiration disea Timothy J Mahony, The University of Queensland, Australia
Lunch Break & Networking: 12:25-13:45	
13:45-14:10	Advax-adjuvanted killed Japanese Encephalitis Virus (JEV) vaccine is safe in

	pregnant mares and in foals and induces robust immunological memory
	Helle Bielefeldt-Ohmann, Australian Infectious Diseases Research Centre, Australia
14:10-14:35	Achievements and challenges in post-exposure vaccine development
	Yuzhang Wu, The Third Military Medical University, China
11:25-11:50	Novel non-genetic approach to improve the tuberculosis vaccine BCG
	Zakaria Hmama, University of British Columbia, Canada
15:30-15:55	Chikungunya Virus vaccines?
	Andreas Suhrbier, QIMR Berghofer Medical Research Institute, Australia
Coffee Break: 15:55-16:10	
16:10-16:35	Kunjin replicon-based vaccine candidate against Ebola virus
	Alexander Khromykh, Australian Infectious Diseases Research Centre, Australia

16:35-17:00	Future prospect of mosquito salivary components as novel target for vector based vaccine against Dengue: Molecular characterization of immunomodulatory protein from salivary glands of Aedes aegypti
	Kartika Senjarini, University of Jember Indonesia, Indonesia
17:00-17:20	Using carriage surveillance to show direct and indirect effects of pneumococcal conjugate vaccine
	Fiona Russell, The University of Melbourne, Australia

Day-2 Key Note	
09:00-09:30	Mohammed Alsharifi The University of Adelaide, Australia
09:00-10:00	Roy Hall The University of Queensland Australia
Coffee Break: 10:30-10:45	

Track 11: Protein Subunits- Vaccination

Track 12: Toxoid vaccines and its importance

Track 14: Vaccines Under Research and Development, Major Diseases

Track 15: Innovative Development of Vaccines

Track 16: Mucosal vaccines

Session Chairs: Kenneth Beagley, **Queensland University of Technology, Australia**
Roy Hall, **Professor of virology, The University of Queensland, Australia**

Session Introduction

10:00-10:25 [Recruitability and Retention: The Challenges of Vaccine Trial design](#)
Suzanne L. Elliott, Q-Pharm, Australia

Coffee Break: 10:25-10:40

10:40-11:05 [Gamma-ray Inactivated Vaccines: Concepts and Applications](#)
Lew-Tabor, The University of Queensland, Australia

- 11:05-11:30 Nasal vaccine using nanoparticles against toxoplasma gondii infection: A mechanistic study
Didier Betbeder, University of Lille, France
- 11:30-11:55 Unique IL-4R antagonist and IL-13Ra2 adjuvanted pox viral vector-based HIV vaccines
Charani ranasinghe, Australian National University, Australia
- 11:55-12:20 Antigen-displaying polyester particles manufactured by engineered bacteria
Bernd Rehm, Massey University, New Zealand

Lunch Break & Networking: 12:20-13:35

Young Research Forum

- 13:35-13:55 Towards the development of oral vaccine delivery systems for lipid core peptide-based vaccines using novel multi-layer engineered nanoliposomes against Group A *streptococcus*
Nirmal Marasini, The university of Queensland, Australia
- 13:55-14:15 A Protective Immune Response Using Asymmetric Multi-Epitope Self-Adjuvanting lipopeptide Vaccine Model
Sharareh Eskandari, The University of Queensland, Australia
- 14:15-14:35 Binding and immune modulation properties of mannosylated lipo-peptide vaccines
Bita Sedaghat, The University of Queensland, Australia
- 14:35-14:55 Best practice for communicating pertussis booster vaccine recommendations to new mothers: A randomised-control trial
Elizabeth Helen Hayles, Division of Women's and Children's Health, Australia
- 14:55-15:15 Liposomes as a Delivery Platform of Vaccines Against Group A *Streptococcus*
Khairunnisa Abdul Ghaffar, University of Queensland, Australia
- 15:15-15:35 Capsular polysaccharide loaded chitosan nanoparticles for mucosal immunization via respiratory tract against *Klebsiella Pneumonia*
Mala Menon, Bombay College of Pharmacy, India

Day-3 Key Note

09:00-09:30 [Istvan Toth](#)
Pharmaceuticals TetraQ, Australia

Coffee Break: 10:30-10:45

Track 2: Developing Next-Gen Conjugate Vaccines

Track 17: Childhood vaccines

Track 18: Cancer vaccines

Track 20: Delivery Technologies

Track 21: Vaccines Business and Development

Session Chair: Mohammed Alsharifi, Director, Chief Scientific Officer, Gamma Vaccines, Australia

Session Introduction

- 09:30-09:55 Vaccine Manufacturing and Clinical Trial Services for Diarrheal Disease Product Development
Rodolfo M. Alarcón, NIH, USA
- 09:55-10:20 Anti-cancer telomerase vaccines: Are they entering the age of maturity?
Gilberto Filaci, Professor, University of Genoa, Italy

Coffee Break: 10:20-10:35

- 10:35-11:00 Impact of Myriad Decisions on Patent Eligibility of Biotechnology Inventions in

Australia and USA

Simon John Potter, Principal, Spruson & Ferguson, Australia

11:00-11:25 [Silica nanocarriers for delivery of single dose – shelf stable nano vaccines](#)

Neena Mitter, The University of Queensland, Australia

11:25-11:50 [Rotavirus vaccines: Development, implementation and impact](#)

Julie E. Bines, University of Melbourne, Australia

11:50-12:15 [How promising is the development of a meningococcal semi-synthetic conjugate vaccine? - a case study](#)

Manoj Kumar Chhikara, Hilleman Labs, India

12:15-12:40 [Non-targeted effects of childhood vaccines: Epidemiological evidence and emerging immunological mechanisms](#)

Katie Flanagan, Monash University, Australia

Lunch Break: 12:40-13:55

13:55-14:20 [Key steps in moving a vaccine from proof of concept in mice to human clinical trials](#)

Mark Reid, Clinical Network Services (CNS) Pty Ltd, Australia

14:20-14:45 [Use of system biology to identify genes associated with enhanced immunogenicity to a skin patch \(nanopatch\) delivered vaccine](#)

Germain J. P. Fernando, University of Queensland, Australia

14:45-15:10 [Immunisation using microspheres of poly glycidyl methacrylate functionalized with MSA-2 peptide to protect cattle from babesiosis](#)

Manuel Rodriguez-Valle, QAAFI/Centre for Animal Science, Australia

15:10-15:35 [A Novel Quantitative Fluorescence Spectroscopy Method to Estimate the Surfactant-Induced Split Ratio of Influenza Virus](#)

Veysel Kayser, The University of Sydney, Australia

Panel Discussion

Award Ceremony